



Announcement no. 9/2008

To the OMX Nordic Exchange Copenhagen

Copenhagen, May 13, 2008

Announcement on rumours

Summary: Discussion of potential transactions with various companies

With reference to an article in Børsen today concerning a potential transaction with Zealand Pharma A/S, Curalogic can confirm that the company has had discussions with Zealand Pharma A/S about a potential transaction but that these discussions are no longer active.

Curalogic is currently in discussions with a number of companies about different potential transactions in line with the strategy for the company, but none of these discussions have reached a point where Curalogic is able to provide further information about details of the discussions or evaluate the probability that Curalogic and one of these parties will reach an agreement.

Yours sincerely,

Curalogic A/S

For additional information, please contact:

Peter Moldt, President and CEO, Phone +45 99 99 24 01
Helle Busck Fensvig, EVP and CFO, Phone +45 99 99 24 03

About Curalogic

Curalogic is a Danish biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen (CUR.CO) as a SmallCap+ company. Curalogic has ample cash resources and has demonstrated its ability to conduct complex clinical studies with a small group of development experts. Curalogic has initiated a search process to identify development projects offering an attractive risk profile. Curalogic expects to conclude an agreement during 2008 that will secure future clinical development projects for the Company.

This announcement contains forward-looking statements regarding the Company's future financial development and performance and other statements which are not historical facts. Such statements are made on the basis of assumptions and expectations which, to the best of the Company's knowledge and belief, are reasonable, at this time, but may prove to be erroneous in the future.